Cargando…
Resumption of anti‐programmed cell death 1 monotherapy for severe immune‐related adverse events experienced patient with renal cell carcinoma
INTRODUCTION: Combined anti‐cytotoxic‐T‐lymphocyte antigen 4 and programmed cell death 1 blockade induced high rates of immune‐related adverse events in patients with renal cell carcinoma. However, the safety of reinitiating anti‐programmed cell death 1 monotherapy for patients who discontinued comb...
Autores principales: | Maegawa, Yoko, Kato, Taigo, Fukuhara, Shinichiro, Kiuchi, Hiroshi, Imamura, Ryoichi, Uemura, Motohide, Nonomura, Norio, Fujita, Kazutoshi |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7469840/ https://www.ncbi.nlm.nih.gov/pubmed/32914066 http://dx.doi.org/10.1002/iju5.12173 |
Ejemplares similares
-
Erectile Dysfunction in Germ Cell Tumor Survivors
por: Okada, Koichi, et al.
Publicado: (2021) -
Seronegative rheumatoid arthritis after combination therapy with ipilimumab and nivolumab for postoperative pancreatic and liver metastases from renal cell carcinoma
por: Nishimura, Yuki, et al.
Publicado: (2022) -
A case of perirenal non‐specific lymphadenitis mimicking a solitary renal mass
por: Umeda, Shun, et al.
Publicado: (2021) -
Mucinous cystadenoma of the renal parenchyma presenting as a Bosniak IIF complex renal cyst
por: Nate, Takanori, et al.
Publicado: (2023) -
A case of mediastinal teratoma with malignant transformation into angiosarcoma and relapse with multiple bone metastases that was cured by a multidisciplinary treatment
por: Tani, Masaru, et al.
Publicado: (2022)